Clinical Trials

Inclusion Criteria:

- Participants must have an unresectable or metastatic solid malignancy that is
histologically or cytologically confirmed to be one of the tumor types listed below:

- Cohorts 1A, 1B, 1C, and 1D

- CRC

- Gastric adenocarcinoma

- GEJ adenocarcinoma

- Esophageal adenocarcinoma

- Cholangiocarcinoma

- Gallbladder carcinoma

- Cohorts 1E, 1F, 1G, and 2A

- Gastric adenocarcinoma

- GEJ adenocarcinoma

- Esophageal adenocarcinoma

- Cohort 2B

- CRC

- Participants must be candidates to receive an oxaliplatin-based regimen as part of
their standard-of-care treatment for all cohorts, except Cohort 1G.

- HER2+ disease, as determined by historic or local laboratory testing

- Phase 1b cohorts: measurable or non-measurable disease according to RECIST v1.1 as
determined by the investigator

- Phase 2 cohorts: measurable disease according to RECIST v1.1 as determined by the
investigator

- Eastern Cooperative Oncology Group Performance Status score of 0 or 1.

Exclusion Criteria:

- History of known hypersensitivity to planned study treatment

- Known to be positive for Hepatitis B or C

- For Cohorts 2A and 2B: prior anti-HER2 therapies

- For Cohorts 1E, 1F, 1G, 2A: Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2
agent or with an agent directed to another stimulatory or co-inhibitory T-cell
receptor (eg, CTLA-4, OX 40, CD137), and was discontinued from that treatment due to a
Grade 3 or higher immune-related adverse event (irAE)

There are additional inclusion criteria. The study center will determine if criteria for participations are met.